Trial Profile
Resistant MS Spasticity Treatment with Sativex and Driving
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Aug 2017
Price :
$35
*
At a glance
- Drugs Nabiximols (Primary)
- Indications Muscle spasticity
- Focus Pharmacodynamics
- Sponsors Almirall S.A.
- 28 Apr 2014 Status changed from active, no longer recruiting to completed as reported by German Clinical Trials Register.
- 02 Oct 2013 Results have been presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) according to a GW Pharmaceuticals media release.
- 20 May 2013 New trial record